Edition:
India

Evelo Biosciences Inc (EVLO.OQ)

EVLO.OQ on NASDAQ Stock Exchange Global Select Market

7.45USD
1:30am IST
Change (% chg)

$0.39 (+5.52%)
Prev Close
$7.06
Open
$7.08
Day's High
$7.65
Day's Low
$7.08
Volume
7,857
Avg. Vol
22,069
52-wk High
$15.86
52-wk Low
$4.91

Latest Key Developments (Source: Significant Developments)

Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data In Psoriasis Patients At Low Dose In Ongoing Phase 1B Trial
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Evelo Biosciences Inc ::EVELO BIOSCIENCES REPORTS POSITIVE EDP1815 INTERIM CLINICAL DATA IN PSORIASIS PATIENTS AT LOW DOSE IN ONGOING PHASE 1B TRIAL.EVELO BIOSCIENCES INC - EDP1815 WAS WELL TOLERATED WITH NO OVERALL DIFFERENCE REPORTED FROM PLACEBO.EVELO BIOSCIENCES INC - PATIENTS DOSED WITH EDP1815 SHOWED A REDUCTION IN MEAN LESION SEVERITY SCORE VERSUS. PLACEBO.EVELO BIOSCIENCES - PHASE 2 INITIATION OF STUDY PLANNED FOR EARLY 2020.  Full Article

Evelo Biosciences Posts Q2 Loss Per Share Of $0.65
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Evelo Biosciences Inc ::EVELO BIOSCIENCES ANNOUNCES POSITIVE INTERIM PHASE 1B CLINICAL DATA AND PROVIDES SECOND QUARTER 2019 FINANCIAL RESULTS.EDP1815 PHASE 2 INITIATION PLANNED FOR EARLY 2020.EDP1815 AND EDP1066 WERE WELL TOLERATED WITH NO OVERALL DIFFERENCE REPORTED FROM PLACEBO.Q2 LOSS PER SHARE $0.65.EVELO BIOSCIENCES - AS OF JUNE 30, 2019, CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $113.5 MILLION VERSUS $178.9 MILLION AS OF JUNE 30, 2018.EVELO BIOSCIENCES - EXPECTS CASH, CASH EQUIVALENTS & INVESTMENTS WILL FUND PLANNED OPERATING EXPENSES & CAPITAL EXPENDITURE REQUIREMENTS INTO Q4 2020.CLINICAL RESPONSE OBSERVED CONSISTENT WITH REDUCTIONS IN CELLULAR HISTOLOGICAL IN PSORIASIS PATIENTS AT LOW DOSE OF EDP1815.EVELO BIOSCIENCES -CLINICAL RESPONSE OBSERVED CONSISTENT WITH REDUCTIONS IN BLOOD IMMUNE CELL BIOMARKERS IN PSORIASIS PATIENTS AT LOW DOSE OF EDP1815.  Full Article

Evelo Biosciences Reports First Quarter 2019 Financial Results And Recent Business Highlights
Thursday, 2 May 2019 

May 2 (Reuters) - Evelo Biosciences Inc ::EVELO BIOSCIENCES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q1 LOSS PER SHARE $0.64.Q1 EARNINGS PER SHARE ESTIMATE $-0.52 -- REFINITIV IBES DATA.PLAN TO INTRODUCE NEW FORMULATION INTO ONGOING CLINICAL TRIALS IN SECOND HALF OF 2019.INITIAL CLINICAL DATA FOR EDP1066 EXPECTED EARLY IN Q3 OF 2019.ON TRACK TO DELIVER 10 CLINICAL READOUTS ACROSS 2019 AND 2020.EVELO BIOSCIENCES - EXPECTS CASH, CASH EQUIVALENTS, INVESTMENTS WILL ENABLE IT TO FUND PLANNED OPERATING EXPENSES & CAPEX REQUIREMENTS INTO H2 2020.  Full Article

Evelo Biosciences Qtrly Net Loss Per Share $0.49
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Evelo Biosciences Inc ::EVELO BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.EVELO BIOSCIENCES INC QTRLY NET LOSS PER SHARE - BASIC AND DILUTED $0.49.EVELO BIOSCIENCES INC - AS OF DECEMBER 31, 2018, CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $147.9 MILLION.EVELO BIOSCIENCES INC - INITIAL CLINICAL DATA FOR EDP1066 IN ATOPIC DERMATITIS AND PSORIASIS EXPECTED IN 2Q 2019.EVELO BIOSCIENCES INC - INITIAL CLINICAL DATA FOR EDP1815 IN ATOPIC DERMATITIS AND PSORIASIS EXPECTED IN 2H 2019.  Full Article